Zoran Zdraveski
General Counsel bei TSCAN THERAPEUTICS, INC.
Vermögen: 2 Mio $ am 30.04.2024
Profil
Zoran Zdraveski is currently the Secretary & Chief Legal Officer at TScan Therapeutics, Inc. He previously worked as the Vice President & Associate General Counsel at Epizyme, Inc. from 2012 to 2017 and as the Secretary & Chief Legal Officer at Magenta Therapeutics, Inc. from 2018 to 2021.
Dr. Zdraveski received his undergraduate degree from Southern Methodist University, his doctorate from Massachusetts Institute of Technology in 2002, and his graduate degree from Suffolk University Law School in 2007.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
TSCAN THERAPEUTICS, INC.
0,52% | 31.03.2024 | 238 436 ( 0,52% ) | 2 Mio $ | 30.04.2024 |
Aktive Positionen von Zoran Zdraveski
| Unternehmen | Position | Beginn |
|---|---|---|
| TSCAN THERAPEUTICS, INC. | General Counsel | 09.09.2021 |
Ehemalige bekannte Positionen von Zoran Zdraveski
| Unternehmen | Position | Ende |
|---|---|---|
| MAGENTA THERAPEUTICS | General Counsel | 01.04.2021 |
| EPIZYME, INC. | Corporate Officer/Principal | 01.04.2017 |
Ausbildung von Zoran Zdraveski
| Massachusetts Institute of Technology | Doctorate Degree |
| Suffolk University Law School | Graduate Degree |
| Southern Methodist University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| TSCAN THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
